Fisher & Paykel Healthcare Set for Medium-Term EPS Growth -- Market Talk

Dow Jones

Jun 02, 2025

0032 GMT - Breathing mask maker Fisher & Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher & Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. "While valuations are elevated, Fisher & Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics," says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher & Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

June 01, 2025 20:32 ET (00:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540755811"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540755811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540755811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540755811","market":"sh","top_or_hot":-1,"title":"Fisher & Paykel Healthcare Set for Medium-Term EPS Growth -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0032 GMT - Breathing mask maker Fisher &amp; Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher &amp; Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. \"While valuations are elevated, Fisher &amp; Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics,\" says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher &amp; Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2025 20:32 ET (00:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisher & Paykel Healthcare Set for Medium-Term EPS Growth -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisher & Paykel Healthcare Set for Medium-Term EPS Growth -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-02 08:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0032 GMT - Breathing mask maker Fisher &amp; Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher &amp; Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. \"While valuations are elevated, Fisher &amp; Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics,\" says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher &amp; Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2025 20:32 ET (00:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"Healthcare Svcs Group Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540755811","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540755811","pubTimestamp":1748824320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0032 GMT - Breathing mask maker Fisher & Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher & Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. \"While valuations are elevated, Fisher & Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics,\" says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher & Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"Healthcare Svcs Group Inc","FPH.NZ":"Fisher & Paykel Healthcare Corporation Limited Ord Shares"},"translate_title":"斐雪派克医疗保健公司将实现中期每股收益增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"FPH.NZ":1},"content_text":"0032 GMT - Breathing mask maker Fisher & Paykel Healthcare adds Morgan Stanley to its bulls despite tariff headwinds in FY 2026. Fisher & Paykel Healthcare's share price eased after its annual result, which analyst David L. Bailey attributes to weaker-than-expected FY 2026 revenue and net profit guidance. Still, MS thinks growth in new apps revenue will support group-wide revenue over the medium term, with margin improvement underpinning attractive EPS growth. \"While valuations are elevated, Fisher & Paykel Healthcare compares favorably relative to the sector on a number of key financial metrics,\" says MS, as it upgrades to the stock overweight from equal-weight. It expects Fisher & Paykel Healthcare will achieve its gross margin target of 65% in FY 2028, and its Ebit margin goal of 30% in FY 2029. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2025 20:32 ET (00:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}